Verastem Company Profile (NASDAQ:VSTM)

Analyst Ratings

Consensus Ratings for Verastem (NASDAQ:VSTM) (?)
Ratings Breakdown: 5 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $3.00 (130.77% upside)

Analysts' Ratings History for Verastem (NASDAQ:VSTM)
Show:
DateFirmActionRatingPrice TargetActions
3/7/2016HC WainwrightReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016Cantor FitzgeraldUpgradeHold -> Buy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Jefferies GroupLower Price Target$18.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Raymond James Financial Inc.DowngradeStrong-Buy -> Outperform$12.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015MizuhoDowngradeBuy -> Neutral$21.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015Roth CapitalDowngradeBuy -> Neutral$23.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2014Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014GuggenheimBoost Price TargetBuy$18.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Verastem (NASDAQ:VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Verastem (NASDAQ:VSTM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20162($0.33)($0.27)($0.30)
Q4 20162($0.34)($0.33)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Verastem (NASDAQ:VSTM)
DateHeadline
07/20/16 08:16 PMVerastem Incorporated (NASDAQ:VSTM) Sellers Covered 9.33% of Their Shorts - Consumer Eagle
07/19/16 07:21 PMVerastem, Inc. (NASDAQ:VSTM): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 06:10 AMTrading Performance and Target Watch for Verastem, Inc. (NASDAQ:VSTM) - Press Telegraph
07/17/16 06:16 AMShares Moving Down on the Week: Verastem, Inc. (NASDAQ:VSTM) - Engelwood Daily
07/16/16 10:21 AMWere Analysts Bearish Verastem Inc (NASDAQ:VSTM) This Week? - Press Telegraph
07/15/16 12:31 PMVerastem : to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
07/13/16 10:01 AMHowland Capital Management Lowers stake in Verastem Inc (VSTM) - Trade Calls
07/12/16 07:25 PMVerastem Inc Institutional Investor Sentiment Worsened in Q1 2016 - Consumer Eagle
07/12/16 07:25 PMVerastem, Inc. (NASDAQ:VSTM) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/10/16 06:01 AMWere Analysts Bullish Verastem Inc (NASDAQ:VSTM) This Week? - Engelwood Daily
07/08/16 09:59 AMVerastem Incorporated (NASDAQ:VSTM) Sellers Covered 9.33% of Their Shorts - Engelwood Daily
07/08/16 09:59 AMVerastem, Inc. (VSTM) Updated Price Targets - FTSE News
07/07/16 09:52 AMVerastem to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
07/06/16 07:41 PMCutting Edge Stocks in Focus - Amedica Corporation (NASDAQ:AMDA), Verastem (NASDAQ:VSTM), HCI Group (NYSE ... - Seneca Globe
07/06/16 06:00 AMVerastem to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday, July 13th at 3:30 PM Eastern Time at Le Parker Meridien New York.
07/05/16 07:31 AMStudy Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer - [at noodls] - - FAK Inhibition Renders Previously Unresponsive Pancreatic Tumors Responsive to Chemo- and Immunotherapy - - Preclinical Results Support Ongoing Phase 1 Clinical Trial in Patients with Pancreatic Cancer ...
07/05/16 05:58 AMVerastem, Inc. (VSTM) Broker Price Targets For The Coming Week - Fiscal Standard
07/03/16 05:49 AMVerastem Incorporated (NASDAQ:VSTM) Shorts Decreased by 9.33% After Short Covering - Press Telegraph
07/02/16 06:36 PMTracking Stock Volatility for: Verastem, Inc. (NASDAQ:VSTM) - Engelwood Daily
07/02/16 06:36 PMWere Analysts Bearish Verastem Inc (NASDAQ:VSTM) This Week? - Engelwood Daily
06/30/16 09:52 AMWatching Stock Volatility for: Verastem, Inc. (NASDAQ:VSTM) - Engelwood Daily
06/28/16 07:06 PMVerastem, Inc. (NASDAQ:VSTM) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 05:43 AMNext Weeks Broker Price Targets For Verastem, Inc. (VSTM) - Fiscal Standard
06/25/16 10:49 AMShare Volatility Check for: Verastem, Inc. (NASDAQ:VSTM) - Press Telegraph
06/25/16 10:49 AMAnalyst's Stocks Rating Activity: UnitedHealth Group Incorporated (NYSE:UNH) , Verastem, Inc. (NASDAQ:VSTM) - Street Updates
06/25/16 10:49 AMHow Analysts Feel About Verastem Inc (NASDAQ:VSTM)? - Press Telegraph
06/20/16 06:40 PMThis Weeks Broker Views For Verastem, Inc. (VSTM) - Fiscal Standard
06/14/16 03:19 PMVerastem Announces Changes to its Board of Directors - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 14, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company's Board of Directors. ...
06/11/16 10:06 AMVerastem Inc. (VSTM) Drops 5.63% on June 09 - Equities.com
06/10/16 07:36 PMVerastem, Inc. (NASDAQ:VSTM) Dropped-5.63%: Waters Corporation (NYSE:WAT), Kaman Corporation (NYSE:KAMN ... - KC Register
06/10/16 04:00 PMVerastem, Inc. :VSTM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/02/16 10:30 AMVerastem, Inc. (NASDAQ:VSTM) Stock Update & Estimates - Stock Tick Tock - Verastem, Inc. (NASDAQ:VSTM) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Verastem, Inc. (NASDAQ:VSTM) to post earnings of $-0.31 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/01/16 06:13 AMVerastem to Present at Upcoming Investor Conferences - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 1, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming ...
05/31/16 10:04 AMSeaDrill (NYSE:SDRL) went up 3.81%: ChemoCentryx (NASDAQ:CCXI), Verastem (NASDAQ:VSTM), Sophiris Bio, Inc ... - KC Register - SeaDrill (NYSE:SDRL) went up 3.81%: ChemoCentryx (NASDAQ:CCXI), Verastem (NASDAQ:VSTM), Sophiris Bio, Inc ...KC RegisterOn 9 May, Verastem, Inc. (NASDAQ:VSTM) reported that, Net loss for the first quarter ended March 31, 2016 (2016 Quarter) was $8.3 million, or $0.22 per share, as compared to a net loss of $15.2 million, or $0.46 per share, for the first quarter ended ...and more »
05/25/16 06:29 PMVerastem Inc. (VSTM) Jumps 9.79% on May 24 - Equities.com - Verastem Inc. (VSTM) Jumps 9.79% on May 24Equities.comVerastem Inc. (VSTM) was among the biggest gainers on the Russell 2000 for Tuesday May 24 as the stock popped 9.79% to $1.57, representing a gain of $0.14 per share. Some 1.22 million shares traded hands on 2,140 trades, compared with an average ...and more »
05/24/16 11:46 PMEarnings Review and Stock Rundown for Verastem, Inc. (NASDAQ:VSTM) - Wall Street Hints and News - Earnings Review and Stock Rundown for Verastem, Inc. (NASDAQ:VSTM)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Verastem, Inc. (NASDAQ:VSTM) to post ...Hold Calls Count For Verastem, Inc. (NASDAQ:VSTM) At 4Equities Focusall 381 news articles »
05/17/16 06:20 PMShare Recap and Earnings Focus on Verastem, Inc. (NASDAQ:VSTM) - Wall Street Hints and News - Share Recap and Earnings Focus on Verastem, Inc. (NASDAQ:VSTM)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Verastem, Inc.and more »
05/16/16 12:03 PMVERASTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/11/16 06:57 PMConsensus Rating Review for Verastem, Inc. (NASDAQ:VSTM) - B.O.D.Y Confidential - Consensus Rating Review for Verastem, Inc. (NASDAQ:VSTM)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2.13 on shares of Verastem, Inc. (NASDAQ:VSTM). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/11/16 06:57 PMResearch Analysts Issue Forecasts for Verastem Inc's Q3 2016 Earnings (VSTM) - Washington News Wire - Washington News WireResearch Analysts Issue Forecasts for Verastem Inc's Q3 2016 Earnings (VSTM)Washington News WireVerastem logo Verastem Inc (NASDAQ:VSTM) – Equities researchers at Jefferies Group issued their Q3 2016 EPS estimates for Verastem in a note issued to investors on Monday, Zacks Investment Research reports. Jefferies Group analyst B. Amin expects ...
05/11/16 06:57 PMAnalysts Offer Predictions for Verastem Inc's FY2018 Earnings (VSTM) - Washington News Wire - Washington News WireAnalysts Offer Predictions for Verastem Inc's FY2018 Earnings (VSTM)Washington News WireVerastem logo Verastem Inc (NASDAQ:VSTM) – Equities research analysts at Roth Capital issued their FY2018 earnings per share (EPS) estimates for shares of Verastem in a report issued on Monday, Zacks Investment Research reports. Roth Capital ...Verastem Inc (VSTM) Lowered to Hold at Zacks Investment ResearchWeb Breaking Newsall 3 news articles »
05/10/16 06:52 PMSizzling HC Stocks Update: Galena Biopharma Inc (GALE), Verastem Inc (VSTM), Omeros Corporation (OMER) - share market updates (press release) - share market updates (press release)Sizzling HC Stocks Update: Galena Biopharma Inc (GALE), Verastem Inc (VSTM), Omeros Corporation (OMER)share market updates (press release)Shares of Galena Biopharma Inc (NASDAQ:GALE) ended Monday session in green amid volatile trading. The shares closed up +0.07 points or 5.60% at $1.32 with 1.05 million shares getting traded. Post opening the session at $1.23, the shares hit an ...and more »
05/09/16 04:24 PMVerastem reports 1Q loss -
05/09/16 04:23 PMVERASTEM, INC. Files SEC form 10-Q, Quarterly Report -
05/09/16 03:28 PMVerastem Reports First Quarter 2016 Financial Results - [at noodls] - BOSTON--(BUSINESS WIRE)--May 9, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, ...
05/08/16 07:08 PMVerastem, Inc. (VSTM) Broker Price Targets For The Coming Week - Share Trading News - Verastem, Inc. (VSTM) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Verastem, Inc. (VSTM). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...How Analysts Feel About Verastem Inc (NASDAQ:VSTM)?Franklin Independentall 2 news articles »
05/05/16 07:08 PMVerastem, Inc. (VSTM) Updated Broker Price Targets - Share Trading News - Verastem, Inc. (VSTM) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Verastem, Inc. (VSTM). The latest reports which are currently in issue on Thursday 5th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Verastem Inc (VSTM) Stock Rating Upgraded by Zacks Investment ResearchWeb Breaking Newsall 2 news articles »
05/04/16 05:06 AMAverage Analyst Rating for Verastem, Inc. (NASDAQ:VSTM) - B.O.D.Y Confidential - Average Analyst Rating for Verastem, Inc. (NASDAQ:VSTM)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 2.13 on Verastem, Inc. (NASDAQ:VSTM) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 06:47 PMVerastem Inc. (VSTM) Drops 5.45% on May 02 - Equities.com - Verastem Inc. (VSTM) Drops 5.45% on May 02Equities.comVerastem Inc. (VSTM) was one of the Russell 2000's biggest losers for Monday May 02 as the stock slid 5.45% to $1.56, a loss of $-0.09 per share. Starting at an opening price of $1.65 a share, the stock traded between $1.51 and $1.67 over the course of ...and more »
05/03/16 08:40 AMVerastem Announces the Presentation of Clinical Data at iMig 2016 - [at noodls] - - VS-6063 generally well tolerated; early signs of tumor reduction observed - - Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naïve patients ...

Social

About Verastem

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VSTM
  • CUSIP: 92337C10
Key Metrics:
  • Previous Close: $1.30
  • 50 Day Moving Average: $1.36
  • 200 Day Moving Average: $1.39
  • P/E Ratio: N/A
  • P/E Growth: -0.69
  • Market Cap: $48.09M
  • Current Year EPS Consensus Estimate: $-1.09 EPS
  • Next Year EPS Consensus Estimate: $-1.07 EPS
Additional Links:
Verastem (NASDAQ:VSTM) Chart for Sunday, July, 24, 2016